scholarly journals Concomitant Essential Thrombocythemia and Mature B -Lymphoproliferative Disorder in a Patient

2021 ◽  
Author(s):  
Ayesha Butt ◽  
Ruhul Quddus ◽  
Natasha Ali
Keyword(s):  
Essential Thrombocythemia ◽  
Lymphoproliferative Disorder ◽  
Leukocyte Count ◽  
Cervical Lymphadenopathy ◽  
Maculopapular Rash ◽  
Blood Film ◽  
Lymphoid Cells ◽  
Janus Kinase ◽  
Lambda Light Chain ◽  
Peripheral Blood Film

A-64-year old male presented with cough, weight loss, and maculopapular rash for 15-20 days. On examination, he was found to have cervical lymphadenopathy and splenomegaly. His leukocyte count was 62.1x109/L, platelets were 1169x109/L and LDH was 816 IU/L. Peripheral blood film showed a leukoerythroblastic picture with thrombocytosis. He was started on hydroxyurea and allopurinol. Subsequently, bone marrow evaluation was done which depicted increased lymphoid cells with an M:E ratio of 4:1. Cellular areas exhibited an increase in myeloid precursors along with prominent lymphoid cells and abundant megakaryocytes. Immunohistochemistry showed an increase in B-lymphocytes. Grade MF-2 reticulin fibrosis was noted. Overall findings suggested essential thrombocythemia (ET). On flow cytometry, CD45-positive lymphoid cells population was 31% and showed reactivity to Pan-B-markers with lambda light chain restriction. Janus Kinase 2 (JAK 2) mutation was detected while BCR-ABL1 translocation was negative. A diagnosis of ET progressing to myelofibrosis and mature B-lymphoproliferative disorder was made. Hydroxyurea and allopurinol were stopped while ruxolitinib was introduced and 2.5 years later he remains stable on this treatment.

scholarly journals Methotrexate-Associated Lymphoproliferative Disorder: Dermoscopic Features

2018 ◽  
Vol 10 (2) ◽  
pp. 149-153 ◽  
Author(s):  
Takeshi Namiki ◽  
Yumiko Sone ◽  
Keiko Miura ◽  
Masaru Tanaka ◽  
Hiroo Yokozeki
Keyword(s):  
Lymphoproliferative Disorder ◽  
Histopathological Examination ◽  
Subcutaneous Tissue ◽  
Lymphoid Cells ◽  
Erythematous Plaque ◽  
Rheumatic Arthritis ◽  
Barr Virus ◽  
Perivascular Infiltrate ◽  
Epstein Barr ◽  
Enhanced Computed Tomography

Methotrexate-related lymphoproliferative disorder (MTX-LPD) is a rare disorder caused by long-term MTX therapy for autoimmune diseases. There has been no report of the dermoscopic features of MTX-LPD to date. A 64-year-old female presented with a slightly elevated indurated erythematous plaque with scales on her right thigh. The patient had been treated for rheumatic arthritis with MTX and prednisolone for more than 15 years, and 18 mg/week MTX without prednisolone had been administered in the last year. Dermoscopy revealed dotted vessels and glomerular vessels on pink homogeneous areas and multiple surface scales. Enhanced computed tomography showed multiple nodules and lymphadenopathies at the mediastinum and axillae. Histopathological examination revealed telangiectasia in the superficial dermis. Atypical lymphoid cells were scattered in the whole dermis and subcutaneous tissue. A perivascular infiltrate of atypical lymphocytes and histiocytoid cells partially destroyed the vessel walls. Epstein-Barr virus in situ hybridization showed a positive result. The cessation of MTX reduced the erythematous plaque, and lymphadenopathies at the neck, mediastinum, and axillae were not palpable. We discuss the relevance of these dermoscopic and histopathological features. The accumulation of such cases will reveal the dermoscopic features of MTX-LPD and the utility of dermoscopy for the diagnosis of MTX-LPD.

scholarly journals THE PERIPHERAL BLOOD FILM

1968 ◽  
Vol 21 (6) ◽  
pp. 788-788
Author(s):  
A. G. Signy
Keyword(s):  
Peripheral Blood ◽  
Blood Film ◽  
Peripheral Blood Film

scholarly journals Sirolimus-Based Immunosuppression Is Associated with Decreased Incidence of Post-Transplant Lymphoproliferative Disorder after Heart Transplantation: A Double-Center Study

2022 ◽  
Vol 11 (2) ◽  
pp. 322
Author(s):  
Rabea Asleh ◽  
Darko Vucicevic ◽  
Tanya M. Petterson ◽  
Walter K. Kremers ◽  
Naveen L. Pereira ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Lymphoproliferative Disorder ◽  
Univariate Analysis ◽  
Mammalian Target Of Rapamycin ◽  
Mtor Inhibitors ◽  
Lymphoid Cells ◽  
Post Transplant ◽  
Barr Virus ◽  
Increased Risk ◽  
Epstein Barr

Mammalian target of rapamycin (mTOR) inhibitors have been shown to reduce proliferation of lymphoid cells; thus, their use for immunosuppression after heart transplantation (HT) may reduce post-transplant lymphoproliferative disorder (PTLD) risk. This study sought to investigate whether the sirolimus (SRL)-based immunosuppression regimen is associated with a decreased risk of PTLD compared with the calcineurin inhibitor (CNI)-based regimen in HT recipients. We retrospectively analyzed 590 patients who received HTs at two large institutions between 1 June 1988 and 31 December 2014. Cox proportional-hazard modeling was used to examine the association between type of primary immunosuppression and PTLD after adjustment for potential confounders, including Epstein–Barr virus (EBV) status, type of induction therapy, and rejection. Conversion from CNI to SRL as primary immunosuppression occurred in 249 patients (42.2%). During a median follow-up of 6.3 years, 30 patients developed PTLD (5.1%). In a univariate analysis, EBV mismatch was strongly associated with increased risk of PTLD (HR 10.0, 95% CI: 3.8–26.6; p < 0.001), and conversion to SRL was found to be protective against development of PTLD (HR 0.19, 95% CI: 0.04–0.80; p = 0.02). In a multivariable model and after adjusting for EBV mismatch, conversion to SRL remained protective against risk of PTLD compared with continued CNI use (HR 0.12, 95% CI: 0.03–0.55; p = 0.006). In conclusion, SRL-based immunosuppression is associated with lower incidence of PTLD after HT. These findings provide evidence of a benefit from conversion to SRL as maintenance therapy for mitigating the risk of PTLD, particularly among patients at high PTLD risk.

scholarly journals Primary cutaneous CD4+ small/medium T-cell lymphoma: a case report

2021 ◽  
Vol 22 (4) ◽  
pp. 199-203
Author(s):  
Jeenam Kim ◽  
Minkyoung Jeong ◽  
Dongkeun Jun ◽  
Myungchul Lee ◽  
Donghyeok Shin ◽  
...  
Keyword(s):  
Case Report ◽  
T Cell ◽  
Lymphoproliferative Disorder ◽  
Cell Lymphoma ◽  
Surgical Excision ◽  
Lymphoid Cells ◽  
The Face ◽  
Single Mass ◽  
Histopathologic Findings

Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder is a rare disease characterized by a single mass on the face or upper part of the trunk. It usually presents an asymptomatic and favorable progression, and its histopathologic findings include small and medium-sized lymphoid cells. The authors report a case of primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder on the forehead. A 51-year-old man presented with a protruding mass on his forehead that the patient had noted 1 month previously. Surgical excision and a permanent biopsy were performed under local anesthesia. Based on the biopsy results, the mass was diagnosed as a primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder. There was no evidence of recurrence at a 15-month follow-up visit.

scholarly journals The potential usefulness of sputum cytology in the conclusive diagnosis of methotrexate-associated lymphoproliferative disorders: A case report

2019 ◽  
Vol 7 ◽  
pp. 2050313X1983601 ◽  
Author(s):  
Seiya Mizuguchi ◽  
Kenichi Mizutani ◽  
Manabu Yamashita ◽  
Hiroshi Minato ◽  
Sohsuke Yamada
Keyword(s):  
B Cell ◽  
Lymphoproliferative Disorder ◽  
Epstein Barr Virus ◽  
B Cell Lymphoma ◽  
Lymphoid Cells ◽  
Sputum Cytology ◽  
Barr Virus ◽  
Large B Cell Lymphoma ◽  
Epstein Barr ◽  
Conclusive Diagnosis

Background: Methotrexate has been used as an anchor drug for the treatment of rheumatoid arthritis and is considered to be a cause of methotrexate-associated lymphoproliferative disorder. Spontaneous regression can occur after withdrawal of methotrexate and may be associated with Epstein–Barr virus positivity and non-diffuse large B cell lymphoma histological type. Methotrexate-associated lymphoproliferative disorders are often diagnosed pathologically by lung biopsy. To the best of our knowledge, there have been no studies on the cytological diagnosis of methotrexate-associated lymphoproliferative disorder using sputum smears. Case: A 70-year-old man, who was diagnosed with rheumatoid arthritis 13 years previously and who had been treated with methotrexate, presented shortness of breath and productive cough. Methotrexate-associated lymphoproliferative disorder was suspected as the sputum cytology showed many atypical lymphoid cells with hyperchromatic enlarged nuclei, foamy cytoplasm and distinct nucleoli. Chest computed tomography revealed multiple nodular shadows with interstitial pneumonia in the bilateral lower lung field. A lung biopsy specimen contained atypical lymphoid cells that were immunohistochemically positive for CD20 and MUM-1, and weakly positive for bcl-6, but negative for CD3 and CD10. There were no Epstein–Barr virus-infectious lymphoid cells by ISH-EBER. He was finally diagnosed with methotrexate-associated lymphoproliferative disorder (non-germinal center B-cell-like diffuse large B cell lymphoma histological type). Most of the nodules disappeared spontaneously following the withdrawal of methotrexate. Discussion and conclusion: A cytologically conclusive diagnosis of methotrexate-associated lymphoproliferative disorder may be reached using sputum smears and clinical information.

Sign in / Sign up

Export Citation Format

Share Document